



HELIX

biopharma

HELIX LOOP

Your inside track on Helix BioPharma – June 2025

We're thrilled to introduce the launch of our **Helix Loop** newsletter—your bi-monthly window into the people, progress, and priorities driving Helix BioPharma forward.

In this inaugural edition, we're recapping key developments from the past six months—from pivotal public milestones to early-stage insights—and sharing what's coming next as we scale up our pipeline, team, and strategic focus.

Thanks for joining us at the start of this new chapter. There's much more ahead.

Inside this issue:

-  Pipeline progress
-  Financing updates
-  Leadership expansion
-  Traction

Pipeline Highlights

- Phase IB in NSCLC: Interactions with the FDA have begun for the Phase IB study of L-DOS47 in combination with pembrolizumab in non-small cell lung cancer (NSCLC).
- CEACAM6 ADCs: We're narrowing down our antibody-drug conjugate (ADC) candidates, aiming to identify a lead candidate in the coming weeks.
- [Helix has closed the acquisitions of pre-IND candidates LEUMUNA™ and GEMCEDA™ with the Laevoroc Group as of 16 May 2025.](#)

Financing

- CAD \$3M private placement closed in January 2025.
- [Bridge financing round of USD \\$13 million in progress, with the support of Kerentech Consulting Ltd.](#)
- Major financing round (USD \$80M) anticipated in 2H 2025.

Building a World Class Team

We've welcomed several key leaders since January:

- **Dr. Thomas Mehrling**, CEO
- **Veronika Kandziora**, COO
- **Dr. Davide Guggi**, CTO
- **Dr. Jonathan Davis**, Director of ADC Discovery
- **Dr. Jessica Kourniakti**, Director of Communications

[Explore the experience behind our expanding leadership team.](#)

Traction

- AGM 2025: All motions passed with over 99% shareholder approval, reinforcing strong alignment around Helix's strategic direction.
- 'Urgent Solutions to Fight Cancer: How Helix BioPharma is Tackling the Toughest Challenges,' [International Business Times](#), 4th April 2025.
- 'Helix BioPharma: Innovating with Purpose, Delivering with Urgency for a New Era in Oncology,' [USA Today](#), 26th April 2025 (only available in the US).

Request a Meeting

We're building value—and momentum. If you're an investor aligned with our vision, we'd love to connect.

[Request a Meeting](#)

If you wish to unsubscribe from our newsletter, click [here](#)